Reliance on the FST to evaluate despair-like behavior is a limitation to this research; however, the FST has been the most effective screening tool for antidepressants over recent decades, and multiple observations that Reelin restores FST immobility suggest that Reelin has potential therapeutic value for treating depression (Armanio, 2021; Allen et al., 2022; Johnston et al., 2023). The gene discussed is RELN; the disease is depressive symptom measurement.